Gastrointestinal side effects are the most commonly reported and include: Nausea affects a significant proportion of patients, particularly during dose escalation Diarrhoea may be mild to moderate and usually improves with time Vomiting less common than nausea but can occur, especially at higher doses Constipation some patients experience reduced bowel movements Abdominal pain or discomfort typically mild but should be monitored Reduced appetite contributes to weight loss but may be excessive in some individuals These gastrointestinal symptoms are generally most pronounced when initiating treatment or increasing the dose
Also, patients with pregnancy, breast feeding, patients suffering from endocrine diseases, autoimmune disorders, chronic debilitating diseases like malignancy, decompensated cardiac, pulmonary, renal, or hepatic diseases were ruled-out
Additionally, GLP-1RAs are recommended for patients with T2DM and chronic kidney disease, and individuals with a history of cardiovascular disease or myocardial infarction may also benefit from GLP-1RAs
Rhmanosus, L